HC Wainwright Reduces Earnings Estimates for Kodiak Sciences

Kodiak Sciences Inc. (NASDAQ:KOD) – Research analysts at HC Wainwright lowered their FY2025 earnings per share (EPS) estimates for Kodiak Sciences in a note issued to investors on Monday, November 17th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings of ($4.35) per share for the year, down from their previous forecast of ($4.10). HC Wainwright currently has a “Buy” rating and a $26.00 target price on the stock. The consensus estimate for Kodiak Sciences’ current full-year earnings is ($3.45) per share. HC Wainwright also issued estimates for Kodiak Sciences’ Q4 2025 earnings at ($1.07) EPS, Q1 2026 earnings at ($0.68) EPS, Q2 2026 earnings at ($0.70) EPS, Q3 2026 earnings at ($0.73) EPS, FY2026 earnings at ($2.88) EPS, FY2027 earnings at ($3.07) EPS, FY2028 earnings at ($2.28) EPS and FY2029 earnings at ($0.82) EPS.

Kodiak Sciences (NASDAQ:KOD) last announced its earnings results on Thursday, November 13th. The company reported ($1.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.09).

A number of other equities research analysts have also recently commented on KOD. JPMorgan Chase & Co. upgraded shares of Kodiak Sciences from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $15.00 to $24.00 in a research note on Friday, October 24th. Lifesci Capital began coverage on shares of Kodiak Sciences in a research note on Thursday, October 23rd. They issued an “outperform” rating and a $40.00 price objective for the company. Jefferies Financial Group assumed coverage on shares of Kodiak Sciences in a research note on Monday, September 22nd. They set a “buy” rating and a $15.00 target price on the stock. Chardan Capital reiterated a “neutral” rating and issued a $14.00 price target on shares of Kodiak Sciences in a research note on Monday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Kodiak Sciences in a report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $22.67.

Kodiak Sciences Price Performance

Shares of KOD stock opened at $19.22 on Wednesday. Kodiak Sciences has a 1 year low of $1.92 and a 1 year high of $22.14. The firm has a fifty day moving average price of $15.53 and a 200-day moving average price of $9.24. The company has a market cap of $1.02 billion, a price-to-earnings ratio of -4.67 and a beta of 2.88.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. US Bancorp DE lifted its stake in shares of Kodiak Sciences by 131.7% during the 1st quarter. US Bancorp DE now owns 9,282 shares of the company’s stock worth $26,000 after acquiring an additional 5,276 shares during the last quarter. Headlands Technologies LLC increased its stake in Kodiak Sciences by 256.4% in the second quarter. Headlands Technologies LLC now owns 8,083 shares of the company’s stock worth $30,000 after purchasing an additional 5,815 shares during the period. Walleye Capital LLC bought a new stake in shares of Kodiak Sciences during the first quarter worth $49,000. Vanguard Personalized Indexing Management LLC boosted its stake in shares of Kodiak Sciences by 21.7% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,070 shares of the company’s stock valued at $56,000 after purchasing an additional 2,691 shares during the period. Finally, Russell Investments Group Ltd. increased its stake in Kodiak Sciences by 729.9% in the 1st quarter. Russell Investments Group Ltd. now owns 21,039 shares of the company’s stock worth $59,000 after buying an additional 18,504 shares during the period. Institutional investors own 89.06% of the company’s stock.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.